Biogen

R&D Project Manager for Gene Therapy Accelerator Unit (GTxAU) (18mo)

Posted on: 12 Feb 2021

Cambridge, MA

Job Description

Company Description

The R&D Project Manager will play a critical role in enabling the successful execution of the gene therapy strategy at Biogen. The role will support the Head of the GTxAU and work closely with key cross-functional stakeholders across Biogen to provide operational guidance, manage key GTxAU forums and initiatives, track progress to goals, and ensure milestones are met on-time. This role will also partner closely with the External Innovation and Business Development teams to understand the innovation landscape in gene therapy and the ongoing deals in the space. Nurturing productive, cross-functional relationships will be key to successful project execution.

Job Description

The R&D Project manager is responsible for partnering with the Head of the GTxAU to ensure effective planning and coordination across gene therapy programs, strategic initiatives, and key forums. The R&D project manager is responsible for collaborating with GTxAU team members to track and manage key activities across the accelerator unit, including cross-functional platform/technology innovation activities, and provide an integrated perspective of GTxAU priorities.

* Ensures high quality project planning and execution by facilitating the identification and tracking of GTxAU goals, and developing and maintaining visibility around initiative status and risks. Identifies, tracks, communicates, and manages critical path activities, and holds team members accountable for functional delivery of plans.
* Supports effective decision making through identification and management of risks and issues, and the creation of integrated GTx timeline scenarios in collaboration with the R&D Project Managers supporting individual GTx programs.
* Proactively and effectively manages project team collaboration, communication planning, and reporting for GTxAU and across key cross-functional stakeholders to ensure completion of deliverables within agreed upon timelines. This includes high quality GTxAU meeting management (agenda management, meeting material preparation and organization, scheduling, meeting minutes, and effective action/decision/issue management). In particular, this role partners with the Head of the GTxAU to manage the GTx R&D Steering Committee, a critical forum for GTx strategy execution.
* Partners with the External Innovation and Business Development teams to support external innovation landscaping efforts and monitor business deal activities in the GTx space.
* Note this is a limited duration employee role of 18 months.

Qualifications

* Minimum 3-7 years of prior project management experience in drug development, in a clinical development, project management, business planning, or pre-clinical development context
* Proficient understanding of R&D drug development processes (pre-clinical and clinical) and biopharmaceutical industry
* Outstanding ability to communicate effectively both verbally and in writing; ability to communicate to a broad range of stakeholders
* Ability to work independently, navigate ambiguity, adapt to change and make rapid, disciplined decisions to enable agile execution
* Commitment to a customer-first culture and motivation to solving complex problems and leading teams to success
* Proven ability to network and collaborate across multiple teams with flexible, positive attitude and ability to get results
* Proficiency with integrated timeline/gantt chart development and technical experience with project management systems & collaboration tools is a plus (e.g. Planisware, Microsoft Project, OnePager Pro/Express, MS Teams, O365 Sharepoint)
* Strong preference will be given to demonstrated familiarity with gene therapy as a therapeutic modality

Education :

* Bachelors Degree required scientific focused degree is a plus
* MBA preferred
* PMP certification or demonstrated Project Management experience is a plus

Additional Information

All your information will be kept confidential according to EEO guidelines.

Biogen

Cambridge, MA

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.

Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.

The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.